IRONWOOD PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $788.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2025-03-31
- IRONWOOD PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $788.00K, a 11.93% increase from fiscal 2023.
- IRONWOOD PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $704.00K.
- IRONWOOD PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2022 was -$290.00K, a 168.08% decline from fiscal 2021.
- IRONWOOD PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2021 was $426.00K, a 31.08% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2024-12-31 | $788.00K 10-K · filed 2025-03-31 |
| 2023-12-31 | $704.00K 10-K · filed 2025-03-31 |
| 2022-12-31 | -$290.00K 10-K · filed 2025-03-31 |
| 2021-12-31 | $426.00K 10-K · filed 2024-02-16 |
| 2020-12-31 | $325.00K 10-K · filed 2023-02-16 |
| 2015-12-31 | $688.00K 10-K · filed 2016-02-19 |
| 2014-12-31 | $1.92M 10-K · filed 2016-02-19 |
| 2013-12-31 | $1.41M 10-K · filed 2016-02-19 |
| 2012-12-31 | $288.00K 10-K · filed 2015-02-18 |
| 2011-12-31 | $245.00K 10-K · filed 2014-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |